Common Stock, $0.18 par value
- Symbol
- ATOS
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Atossa Therapeutics, Inc.
ATOSNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. On September 29, 2026, Atossa Therapeutics, Inc. (the “Company”) announced that its board of directors has approved a plan to issue one contingent value right to each share of the Company’s common stock to enable stockholders to share in a portion of any proceeds received from the monetization of the Company’s first qualifying rare pediatric disease priority review voucher.…
Company context
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need. The Company's lead product candidate, (Z)-endoxifen, is in development across several clinical settings, including potential applications in oncology and rare diseases. Atossa has received FDA Orphan Drug Designation for (Z)-endoxifen for Duchenne muscular dystrophy and Rare Pediatric Disease designations for Duchenne muscular dystrophy and McCune-Albright syndrome. (Z)-endoxifen is not approved for any indication. More information is available at atossatherapeutics.com.
Current securities
Historical securities (1)
Registered securities in this filing
Atossa Therapeutics, Inc. · 8-K · Filed 2026-09-29
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On September 29, 2026, Atossa Therapeutics, Inc. (the “Company”) announced that its board of directors has approved a plan to issue one contingent value right to each share of the Company’s common stock to enable stockholders to share in a portion of any proceeds received from the monetization of the Company’s first qualifying rare pediatric disease priority review voucher. A copy of the related press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Filed exhibits (1)
Exhibit 99.1 Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher Shareholders would receive one CVR for each ATOS share held as of the record date or issued thereafter CVRs would entitle holders to 25% of net proceeds from monetization of Atossa’s first qualifying priority review voucher, subject to a $50 million aggregate payment cap SEATTLE, September 29, 2026 - Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need, today announced that its Board of Directors has approved a plan to issue one contingent value right (“CVR”) for each share of Atossa common stock to enable shareholders to share in a portion of any proceeds received from the monetization of Atossa’s first qualifying rare pediatric disease priority review voucher. The CVR would give shareholders a contractual right to participate in the potential future value of the first qualifying FDA priority review voucher arising from an Atossa development program. Under the CVR agreement, holders w…
Open exhibit ↗